IMRX Insider Trading
Insider Ownership Percentage: 25.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Immuneering Share Price & Price History
Current Price: $1.29
Price Change: ▲ Price Increase of +0.05 (4.03%)
As of 04/11/2025 05:00 PM ET
Immuneering Insider Trading History
Immuneering Institutional Trading History
Data available starting January 2016
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Read More on Immuneering
Volume
140,870 shs
Average Volume
2,349,749 shs
Market Capitalization
$46.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Immuneering?
Immuneering's top insider shareholders include:
- Cormorant Asset Management, Lp (Major Shareholder)
- Benjamin J Zeskind (CEO)
- Peter Feinberg (Director)
- Ann E Berman (Director)
- Leah R Neufeld (Insider)
- Mallory Morales (CAO)
- Harold Eugene Brakewood (Insider)
Learn More about top insider investors at Immuneering.